# Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma

> **NCT05338879** · — · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 247 (actual)

## Conditions studied

- Relapsed/Refractory Follicular Lymphoma

## Interventions

- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT05338879
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-22
- **Primary completion:** 2023-10-05
- **Final completion:** 2023-10-05
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05338879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05338879, "Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05338879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*